In 2017, Eurofins Scientific, a biopharmaceutical testing firm acquired Amatsigroup SAS to support Eurofins’ extensive drug development platform. Starting July 2, 2019 the commercial brand for Eurofins Amatsigroup is now Eurofins CDMO, falling under the contract development and manufacturing organization (CDMO) umbrella in conjunction with Eurofins’ operations in North America and India. Eurofins CDMO provides integrated, end-to-end solutions for pre-clinical and clinical outsourcing services of both drug substance/API and drug product manufacturing for biologics and small molecules.
 
Eurofins CDMO’s capabilities include:
 
• Supporting clients to move rapidly through the drug development value chain;
• Performing complex formulation screening and development for sterile and non-sterile manufacturing;
• Accelerating process development and scale-up under GMP compliance;
• Supplying clinical trial materials including packaging and logistics; and
• Provide regulatory compliance throughout each stage of the development cycle.